Product ID: SQMIG35I2293
Global Multiple Myeloma Market Size, Share, Growth Analysis, By Therapy(Targeted Therapy, Biologic Therapy), By Drug type(Immunomodulatory Drugs, Proteasome Inhibitors), By Distribution channel(Hospital Pharmacies, Retail Pharmacies) - Industry Forecast 2024-2031
Report ID:
SQMIG35I2293 |
Region:
Global |
Published Date: April, 2024
Pages:
157
|
Tables:
94 |
Figures:
76
Global Multiple Myeloma Market Dynamics
Multiple Myeloma Market Driver
- The use of monoclonal antibodies with a high safety profile to attack myeloma cells. The development of nanomedicine platforms, the increased use of microRNA therapies, and the ongoing development of efficient and safe medications are all contributing to the growth of the multiple myeloma market. When monoclonal antibodies and histone deacetylase (HDAC) inhibitors are added to the current treatment options, the medication market is expected to grow. Clinicians prefer biologic therapy with monoclonal antibodies such as Darzalex and Empliciti due to their well-documented clinical profile.
- Hematological cancer is becoming more common. The rate of expansion of the multiple myeloma market is predicted to be accelerated by the rising incidence of hematological malignancy called multiple myeloma is brought on by particular genetic flaws. Medications that alter the immune system are used to treat the illness and increase the effectiveness of stem cell transplants, radiation therapy, chemotherapy, and platelet transfusions to drive the market growth.
- The increasing cost of healthcare contributes to the infrastructure of the multiple myeloma market, which is another important element driving its growth rate. The market for multiple myeloma will also grow as the elderly population grows and as the number of fat people rises.
Multiple Myeloma Market Restraint
- Low treatment rates in emerging nations due to the high cost of multiple myeloma treatment would hinder the market's growth pace. Multiple myeloma will face challenges from a lack of skilled workers and a lack of healthcare infrastructure in developing nations. Additionally, a decrease in clinical visits brought on by the COVID-19 outbreak and a lack of public awareness may constrain and impede the market's growth rate throughout the projection period.
Global Multiple Myeloma Market Report Snapshots
Want to customize this report?
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATION
USA (+1) 351-333-4748
